Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [33]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citation(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032
Research works printed but not linked: 8
- Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
- Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
- Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
- Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
- Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
- Lukas, J. et al. Oncogene (in the press).
Cited by
Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
The Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,422
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Self-citationA p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
Hannigan, G. E., Leung-Hagesteijn, C., Fitz-Gibbon, L., Coppolino, M. G., Radeva, G., Filmus, J., Bell, J. C., & Dedhar, S. (1996) · Nature · doi:10.1038/379091a0 · Cited by 1,110
Murray, A. W. (2004) · Cell · doi:10.1016/s0092-8674(03)01080-8 · Cited by 1,053
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008
The INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
Nevins, J. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.699 · Cited by 922
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
The ankyrin repeat as molecular architecture for protein recognition
Mosavi, L. K., Cammett, T. J., Desrosiers, D. C., & Peng, Z. (2004) · Protein Science · doi:10.1110/ps.03554604 · Cited by 907
“These mutants have greatly reduced affinity for Cdk4 and Cdk6 and are deficient in cell cycle inhibitory www.proteinscience.org 1443 function (Lukas et al. 1995; Reymond and Brent 1995; Walker et al. 1999).”
BackgroundThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Self-citationFunctional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
DNA Replication Stress as a Hallmark of Cancer
Macheret, M., & Halazonetis, T. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040424 · Cited by 823
Molecular genetics of prostate cancer
Abate-Shen, C., & Shen, M. M. (2000) · Genes & Development · doi:10.1101/gad.819500 · Cited by 735
“Another cell cycle regulator of particular interest is p16, because its alteration is inversely correlated with that of Rb in other carcinomas (Otterson et al. 1994; Lukas et al. 1995; Ueki et al. 1996), and its loss is significant for bypassing senescence in many cell types, including prostate epithelial cells (Jarra…”
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
Self-citationCYCLINS AND CELL CYCLE CHECKPOINTS
Johnson, D. G., & Walker, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.295 · Cited by 719
Regulation of p16 CDKN2 Expression and Its Implications for Cell Immortalization and Senescence
Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.859 · Cited by 733
“The p16 was then detected with the DCS-50 mouse monoclonal antibody against the C terminus of human p16 (31).”
BackgroundMethodSelf-citationSignalling, cell cycle and pluripotency in embryonic stem cells
Burdon, T., Smith, A., & Savatier, P. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)02352-8 · Cited by 711
Kitagawa, M., Higashi, H., Jung, H. K., Suzuki-Takahashi, I., Ikeda, M., Tamai, K., Kato, J., Segawa, K., Yoshida, E., Nishimura, S., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01097.x · Cited by 589
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.
Reed, A. L., Califano, J. A., Cairns, P., Westra, W. H., Jones, R. M., Koch, W. M., Ahrendt, S. A., Eby, Y. J., Sewell, D. A., Nawroz, H., et al. (1996) · PubMed · Cited by 662
Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D
Schmidt, M., Fernandez de Mattos, S., van der Horst, A., Klompmaker, R., Kops, G. J. P. L., Lam, E. W.-F., Burgering, B. M. T., & Medema, R. H. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7842-7852.2002 · Cited by 562
p16 INK4A is a robust in vivo biomarker of cellular aging in human skin
Ressler, S., Bartkova, J., Niederegger, H., Bartek, J., Scharffetter‐Kochanek, K., Jansen‐Dürr, P., & Wlaschek, M. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00231.x · Cited by 557
Gene-promoter hypermethylation as a biomarker in lung cancer
Belinsky, S. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1432 · Cited by 533
Shackelford, R. E., Kaufmann, W. K., & Paules, R. S. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00224-0 · Cited by 524
Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
Identification of CDK4 as a target of c-MYC
Hermeking, H., Rago, C., Schuhmacher, M., Li, Q., Barrett, J. F., Obaya, A. J., O'Connell, B. C., Mateyak, M. K., Tam, W., Kohlhuber, F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050586197 · Cited by 471
Centrosome duplication in mammalian somatic cells requires E2F and Cdk2–Cyclin A
Meraldi, P., Lukas, J., Fry, A. M., Bartek, J., & Nigg, E. A. (1999) · Nature Cell Biology · doi:10.1038/10054 · Cited by 475
“Progression towards S phase is controlled by the phosphorylation state of the Rb protei”
BackgroundSelf-citationProliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
Rocco, J. W., & Sidransky, D. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5149 · Cited by 470
“Several studies have demonstrated that expression of p16 arrests tumor cells at the G1/S interface in a pRb-dependent manner [20, 21].”
BackgroundRB1: a prototype tumor suppressor and an enigma
Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 435
“…and it is mutated at lower frequencies in a variety of other cancer types. pRB is often described as a component of a regulatory pathway that is inactivated in most cancers (the INK4A/Cyclin D1/pRB/E2F pathway) (Kato et al. 1993; Aagaard et al. 1995; Koh et al. 1995; Lukas et al. 1995; Sherr 1996).”
BackgroundINK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442
Prall, O. J., Sarcevic, B., Musgrove, E. A., Watts, C. W., & Sutherland, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10882 · Cited by 444
Cell-cycle inhibitors: three families united by a common cause
Vidal, A., & Koff, A. (2000) · Gene · doi:10.1016/s0378-1119(00)00092-5 · Cited by 431
Connell-Crowley, L., Harper, J. W., & Goodrich, D. W. (1997) · Molecular Biology of the Cell · doi:10.1091/mbc.8.2.287 · Cited by 407
“Phosphopeptide Mapping and Phosphoamino Acid Analysis In vitro-phosphorylated pRb was separated by SDS-PAGE in 12% gels, transferred to nitrocellulose, and trypsinized as described (Luo et al., 1991).”
MethodCdk inhibitors in development and cancer
Wade Harper, J., & Elledge, S. J. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90011-8 · Cited by 399
The retinoblastoma protein pathway and the restriction point
Bartek, J., Bartkova, J., & Lukas, J. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80081-0 · Cited by 390
Self-citationSoufir, N. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.209 · Cited by 386
“Wild-type P16 arrests normal diploid cells in late G1 phase, whereas a tumor-associated mutant of P16 does not ( 17 ,18).”
BackgroundBelinsky, S. A., Liechty, K. C., Gentry, F. D., Wolf, H. J., Rogers, J., Vu, K., Haney, J., Kennedy, T. C., Hirsch, F. R., Miller, Y., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3408 · Cited by 389
Cyclin D1 is an essential mediator of apoptotic neuronal cell death.
Kranenburg, O., van der Eb, A. J., & Zantema, A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00332.x · Cited by 379
Adams, P. D., Sellers, W. R., Sharma, S. K., Wu, A. D., Nalin, C. M., & Kaelin, W. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6623 · Cited by 373
Gene methylation in gastric cancer
Qu, Y., Dang, S., & Hou, P. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.05.002 · Cited by 373
Kuiper, R. P., Schoenmakers, E. F. P. M., van Reijmersdal, S. V., Hehir-Kwa, J. Y., van Kessel, A. G., van Leeuwen, F. N., & Hoogerbrugge, P. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404691 · Cited by 365
Cyclin E-induced S phase without activation of the pRb/E2F pathway.
Lukas, J., Herzinger, T., Hansen, K., Moroni, M. C., Resnitzky, D., Helin, K., Reed, S. I., & Bartek, J. (1997) · Genes & Development · doi:10.1101/gad.11.11.1479 · Cited by 378
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
“Through this ability to antagonize cyclin D1 function, p16ink4a blocks cell cycle progression, and the antiproliferative action of p16ink4a is dependent both on the presence of CDK4/6 activity and RB (Koh et al., 1995; Lukas et al., 1995b).”
BackgroundAmati, B. (1998) · Frontiers in Bioscience · doi:10.2741/a239 · Cited by 367
Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein
Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J., Bernards, R., DeCaprio, J. A., & Ewen, M. E. (1997) · Nature · doi:10.1038/386177a0 · Cited by 357
Zhang, H. S., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)80714-x · Cited by 349
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
“The p16 INK4A protein is induced by oncogenic stresses to suppress tumorigenesis; however, tumours lacking RB are able to proliferate despite high levels of p16 INK4A expressio”
The retinoblastoma gene family: cousins with overlapping interests
Mulligan, G. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01470-x · Cited by 336
A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers
Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., et al. (2011) · Nature · doi:10.1038/nature10155 · Cited by 333
The INK4 family of cell cycle inhibitors in cancer
Roussel, M. F. (1999) · Oncogene · doi:10.1038/sj.onc.1202998 · Cited by 322
“Enforced expression of INK4 proteins arrests cells in the G1 phase, in a pRB-dependent fashion (Lukas et al., 1995; Medema et al., 1995).”
BackgroundLukas, J., Bartkova, J., & Bartek, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6917 · Cited by 327
“directly phosphorylating pRb in mid to late G1 (34, 36, 38).”
BackgroundMethodInfluentialSelf-citationMC1R Genotype Modifies Risk of Melanoma in Families Segregating CDKN2A Mutations
Box, N. F., Duffy, D. L., Chen, W., Stark, M., Martin, N. G., Sturm, R. A., & Hayward, N. K. (2001) · The American Journal of Human Genetics · doi:10.1086/323412 · Cited by 310
Chinni, S. R., Li, Y., Upadhyay, S., Koppolu, P. K., & Sarkar, F. H. (2001) · Oncogene · doi:10.1038/sj.onc.1204365 · Cited by 315
“…of each phase of cell cycle by associating with corresponding phase speci®c CDKs. Cyclin D isoforms associate with CDK4 and CDK6 and this association leads to activation of CDK4 and CDK6, which help maintaining and progressing through the early G1 phase of the cell cycle (Lukas et al., 1995a,b).”
BackgroundRole of CXCL1 in tumorigenesis of melanoma
Dhawan, P., & Richmond, A. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.9 · Cited by 303
Novitch, B. G., Mulligan, G. J., Jacks, T., & Lassar, A. B. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.2.441 · Cited by 304
“Recent studies have similarly found that the p16 family of Cdk inhibitors lack growth inhibitory function in cells lacking pRb (Guan et al., 1994; Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995).”
BackgroundLukas, J., Petersen, B. O., Holm, K., Bartek, J., & Helin, K. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1047 · Cited by 303
“The expression plasmids pCMVE2F-1, pCMVE2F-1 (Y411C), pCMVE2F-1 (E132), and pCMVE2F-1(1-374) have been described before (21, 22).”
BackgroundMethodSelf-citationE2F4 and E2F5 Play an Essential Role in Pocket Protein–Mediated G1 Control
Gaubatz, S., Lindeman, G. J., Ishida, S., Jakoi, L., Nevins, J. R., Livingston, D. M., & Rempel, R. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00071-x · Cited by 300
Ezhevsky, S. A., Nagahara, H., Vocero-Akbani, A. M., Gius, D. R., Wei, M. C., & Dowdy, S. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10699 · Cited by 280
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
Lukas, C., Sørensen, C. S., Kramer, E., Santoni-Rugiu, E., Lindeneg, C., Peters, J.-M., Bartek, J., & Lukas, J. (1999) · Nature · doi:10.1038/44611 · Cited by 284
Self-citationKnudsen, E. S., & Wang, J. Y. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5771 · Cited by 286
“Another line of evidence supporting the idea that phosphorylation of RB is required for G1/S progression comes from studies of p16 INK4 , an inhibitor of cdk4-cdk6 (29, 35 , 36).”
BackgroundResultInfluentialCyclin dependent kinase regulation
Lees, E. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80060-3 · Cited by 285
Whelan, A. J., Bartsch, D., & Goodfellow, P. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331505 · Cited by 280
Lung cancer epigenetics: From knowledge to applications
Duruisseaux, M., & Esteller, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.005 · Cited by 283
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9–mediated leukemogenesis
Nguyen, A. T., Taranova, O., He, J., & Zhang, Y. (2011) · Blood · doi:10.1182/blood-2011-02-334359 · Cited by 275
p16INK4A and p19ARF act in overlapping pathways in cellular immortalization
Carnero, A., Hudson, J. D., Price, C. M., & Beach, D. H. (2000) · Nature Cell Biology · doi:10.1038/35004020 · Cited by 279
“This observation is consistent with numerous reports that show that p16 INK4A and Rb operate in the same pathwa”
ResultBrugarolas, J., Moberg, K., Boyd, S. D., Taya, Y., Jacks, T., & Lees, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.3.1002 · Cited by 276
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bártková, J., Lukáš, J., Guldberg, P., Alsner, J., Kirkin, A. F., Zeuthen, J., & Bártek, J. (1996) · PubMed · Cited by 303
Wong, D. J., Paulson, T. G., Prevo, L. J., Galipeau, P. C., Longton, G., Blount, P. L., & Reid, B. J. (2001) · PubMed · Cited by 274
Suzuki, T., Kitao, S., Matsushime, H., & Yoshida, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00505.x · Cited by 269
Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells
Parisi, T. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg482 · Cited by 264
Development of mice expressing a single D-type cyclin
Ciemerych, M. A., Kenney, A. M., Sicinska, E., Kalaszczynska, I., Bronson, R. T., Rowitch, D. H., Gardner, H., & Sicinski, P. (2002) · Genes & Development · doi:10.1101/gad.1023602 · Cited by 267
“Ectopic expression of D-cyclins’ inhibitor, p16INK4a, was shown to block the proliferation of several cell types, underscoring a critical, essential function for D-cyclins in cell cycle progression (Lukas et al. 1995a; Ortega et al. 2002).”
BackgroundThe E2F transcription factors: key regulators of cell proliferation
Müller, H., & Helin, K. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00030-x · Cited by 260
Cell cycle control, checkpoint mechanisms, and genotoxic stress.
Shackelford, R. E., Kaufmann, W. K., & Paules, R. S. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107s15 · Cited by 257
Herschkowitz, J. I., He, X., Fan, C., & Perou, C. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2142 · Cited by 255
“It is also well-known that cell cycle inhibition by p16INK4a is RBdependent [ 48 ] and, therefore, these RB1-deficient breast tumours would be expected to be refractory to the high levels of p16INK4a.”
BackgroundRB kinases and RB-binding proteins: new points of view
Taya, Y. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10070-0 · Cited by 257
Role of the retinoblastoma protein in the pathogenesis of human cancer.
Sellers, W. R., & Kaelin, W. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3301 · Cited by 253
The Retinoblastoma Protein Pathway in Cell Cycle Control and Cancer
Bartek, J., Bartkova, J., & Lukas, J. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3776 · Cited by 254
Self-citationCombinatorial patterns of somatic gene mutations in cancer
Yeang, C.-H., McCormick, F., & Levine, A. (2008) · The FASEB Journal · doi:10.1096/fj.08-108985 · Cited by 251
The Retinoblastoma Protein: A Master Regulator of Cell Cycle, Differentiation and Apoptosis
Herwig, S., & Strauss, M. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00581.x · Cited by 250
Self-citationSwanton, C. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01321-4 · Cited by 248
Kim, J. H., Yoon, S. Y., Kim, C.-N., Joo, J. H., Moon, S. K., Choe, I. S., Choe, Y.-K., & Kim, J. W. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.07.009 · Cited by 247
pRB plays an essential role in cell cycle arrest induced by DNA damage
Harrington, E. A., Bruce, J. L., Harlow, E., & Dyson, N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11945 · Cited by 242
Id2 Specifically Alters Regulation of the Cell Cycle by Tumor Suppressor Proteins
Lasorella, A., Iavarone, A., & Israel, M. A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.6.2570 · Cited by 241
Regulation of CDK/cyclin complexes during the cell cycle
Arellano, M., & Moreno, S. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00178-1 · Cited by 236
Metadata
- Authors
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- ORCID
- Mann, David J.
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2010493387
- Cited by
- 899
- References
- 28
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 22 · 2012: 16
- FWCI
- 32.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, retinoblastoma protein, CDKN2, tumour suppressor, cell cycle arrest, G1 phase progression, D-type cyclins, CDK4, CDK6, retinoblastoma, carcinogenesis, chromosome 9p21
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Cells, Cultured, Cloning, Molecular, Escherichia coli, Humans, Mice, Inbred BALB C, Microinjections, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Tumor Cells, Cultured, Oncogene Proteins, Genes, Tumor Suppressor, Retinoblastoma Protein, G1 Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.